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A major challenge in HIV research since the 
onset of the AIDS epidemic more than 30 years 
ago has been the development of an effective 
prophylactic vaccine. Most effective prophylac-
tic vaccines directed against human pathogens 
elicit neutralizing antibodies (NAbs; Amanna 
and Slifka, 2011). Historically, monoclonal and 
polyclonal NAbs have been passively adminis-
tered to susceptible humans and animals to pre-
vent virus-induced disease (Keller and Stiehm, 
2000; Buchwald and Pirofski, 2003). However, 
because HIV-1 infections, once established, 
nearly invariably lead to fatal outcomes, effec-
tive passively transferred antibodies must block 
virus acquisition to prevent disease. The pas-
sive transfer of early generations of anti–HIV-1 
mAbs demonstrated that they could confer 
sterilizing protection in macaques against chal-
lenges with SHIVs (Mascola et al., 1999; Baba 
et al., 2000; Parren et al., 2001). However, the 
amounts of antibody required to prevent virus 
acquisition were so high that it was believed 
that this type of protection was not achievable 
by vaccination.
During the past four to five years, a new 
generation of potent, broadly acting, neutralizing 
CORRESPONDENCE  
Malcolm A. Martin:  
malm@nih.gov  
OR  
Yoshiaki Nishimura:  
ynishimura@niaid.nih.gov
Abbreviations used: AID50, 
animal infectious dose50; CD4bs, 
CD4 binding site; IR, intrarec-
tal; NAb, neutralizing antibody; 
PI, post infection.
G.J. Nabel’s present address is Sanofi, Cambridge, MA 02139.
Passive transfer of modest titers of potent  
and broadly neutralizing anti-HIV monoclonal 
antibodies block SHIV infection in macaques
Masashi Shingai,1 Olivia K. Donau,1 Ronald J. Plishka,1 Alicia Buckler-White,1 
John R. Mascola,2 Gary J. Nabel,2 Martha C. Nason,3 David Montefiori,4  
Brian Moldt,5,6,7 Pascal Poignard,5,6,7 Ron Diskin,8 Pamela J. Bjorkman,9,10 
Michael A. Eckhaus,11 Florian Klein,12 Hugo Mouquet,13  
Julio Cesar Cetrulo Lorenzi,12 Anna Gazumyan,12 Dennis R. Burton,5,6,7,14 
Michel C. Nussenzweig,10,12 Malcolm A. Martin,1 and Yoshiaki Nishimura1
1Laboratory of Molecular Microbiology, 2Virology Laboratory, Vaccine Research Center, and 3Biostatistics Research Branch, 
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
4Department of Surgery, Duke University Medical Center, Durham, NC 27710
5Department of Immunology and Microbial Science, 6IAVI Neutralizing Antibody Center, and 7Center for HIV/AIDS Vaccine 
immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037
8Department of Structural Biology, Weizmann Institute of Science, Rehovot 7610001, Israel
9Division of Biology, California Institute of Technology, Pasadena, CA 91125
10Howard Hughes Medical Institute, Chevy Chase, MD 20815
11Diagnostic and Research Services Branch, Office of the Director, National Institutes of Health, Bethesda, MD 20892
12Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065
13Laboratory of Humoral Response to Pathogens, Department of Immunology, Institut Pasteur, 75724 Paris, France
14Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Boston, MA 021142
It is widely appreciated that effective human vaccines directed against viral pathogens 
elicit neutralizing antibodies (NAbs). The passive transfer of anti–HIV-1 NAbs conferring 
sterilizing immunity to macaques has been used to determine the plasma neutralization 
titers, which must be present at the time of exposure, to prevent acquisition of SIV/HIV 
chimeric virus (SHIV) infections. We administered five recently isolated potent and broadly 
acting anti-HIV neutralizing monoclonal antibodies (mAbs) to rhesus macaques and chal-
lenged them intrarectally 24 h later with either of two different R5-tropic SHIVs. By 
combining the results obtained from 60 challenged animals, we determined that the pro-
tective neutralization titer in plasma preventing virus infection in 50% of the exposed 
monkeys was relatively modest (1:100) and potentially achievable by vaccination.
This article is distributed under the terms of an Attribution–Noncommercial–Share 
Alike–No Mirror Sites license for the first six months after the publication date 
(see http://www.rupress.org/terms). After six months it is available under a Cre-
ative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported 
license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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is a molecularly cloned derivative of SHIVAD8 (Nishimura 
et al., 2010), replicates to high levels in rhesus macaque 
PBMCs, exhibits a Tier 2 neutralization sensitivity phenotype 
(Gautam et al., 2012), and generates sustained levels of plasma 
viremia and depletion of CD4+ T cells leading to symptom-
atic immunodeficiency in inoculated monkeys. The second 
R5-tropic SHIV, SHIVDH12-V3AD8, was newly constructed by 
inserting the entire 33 amino acid gp120 V3 coding region 
of SHIVAD8EO, which confers the capacity to use the CCR5 
coreceptor for cell entry, into the genetic background of the 
previously described X4-tropic SHIVDH12-CL-7 (Fig. 1 A; 
Sadjadpour et al., 2004). SHIVDH12-V3AD8 exhibits robust 
replication kinetics during infection of rhesus monkey PBMC 
and exclusively utilizes CCR5 to enter these cells (Fig. 1, 
B and C). The gp120s of SHIVDH12-V3AD8 and SHIVAD8EO differ 
by 10% at the nucleotide level. Their sensitivities to a panel of 
sera from HIV-1–infected individuals exhibiting a wide range 
of neutralizing activity indicates that both possess a Tier 2 anti–
HIV-1 neutralization phenotype (Table 1). Rhesus macaques 
inoculated intravenously or intrarectally with SHIVDH12-V3AD8 
exhibited peak levels of plasma viremia ranging from 105 to 107  
viral RNA copes/ml of plasma at weeks 2 to 3 post infection 
(PI; Fig. 1, D and E).
The neutralization sensitivity of SHIVAD8EO to 11 recently 
reported broadly reactive anti–HIV-1 mAbs was initially deter-
mined in the TZM-bl assay system. Eight of these antibodies 
(VRC01 [Zhou et al., 2010], NIH45-46 [Diskin et al., 
2011], 45–46G54W [Diskin et al., 2011], 45-46m2 [Diskin 
et al., 2013], 3BNC117 [Scheid et al., 2011], 12A12 [Scheid 
et al., 2011], 1NC9 [Scheid et al., 2011], and 8ANC195 [Scheid 
mAbs have been isolated from HIV-1–infected individuals 
(Burton et al., 2012; Kwong and Mascola, 2012; Klein et al., 
2013b). These mAbs target the CD4 binding site (CD4bs), 
protein-glycan epitopes associated with the gp120 V1/V2, 
V3, and V4 regions, and the membrane proximal external re-
gion of gp41 (Walker et al., 2009, 2010, 2011a; Wu et al., 
2010; McLellan et al., 2011; Scheid et al., 2011; Huang et al., 
2012; Kong et al., 2013) and typically exhibit great breadth 
and potency against heterologous HIV-1 isolates when as-
sayed for neutralization in vitro. In this study, five of the new 
neutralizing mAbs were individually administered to groups 
of rhesus macaques, which were subsequently separately chal-
lenged intrarectally with either of two different R5 SHIVs. 
Levels of HIV-1 NAbs in the blood and tissues were measured 
at the time of virus challenge. By combining the results ob-
tained from 60 animals challenged with two different SHIVs, 
we determined that the plasma neutralization titer preventing 
virus acquisition was relatively modest (1:100) and poten-
tially achievable by vaccination. These findings provide guid-
ance for determining the levels of neutralizing activity in 
plasma that an effective HIV vaccine should elicit.
RESULTS
In vitro characterization of 11 broadly reactive  
anti-HIV NAbs against two R5-tropic SHIVs
The neutralization sensitivities of two different R5-tropic 
SHIVs, to be subsequently used as challenge viruses in the 
preexposure passive antibody experiments described below, 
were assessed using the TZM-bl cell neutralization assay. One 
of the R5 SHIVs evaluated, SHIVAD8EO (Shingai et al., 2012), 
Figure 1. Construction and characterization of 
the R5-tropic SHIVDH12-V3AD8. (A) The entire gp120 
V3 region of the X4-tropic SHIVDH12-CL7 (Sadjadpour  
et al., 2004) was replaced with the gp120 V3 region 
from the R5-tropic SHIVAD8EO (Shingai et al., 2012) by 
PCR-mediated mutagenesis. The red letters indicate 
the amino acid changes from the SHIVAD8EO V3 loop 
conferring R5 tropism to SHIVDH12-V3AD8. Virus stocks of 
the resultant SHIVDH12-V3AD8 were prepared in Concana-
valin A–stimulated macaque PBMC using 293T cell 
transfection supernatants. (B) The coreceptor utiliza-
tion of SHIVDH12-V3AD8 was compared with that of the 
previously described X4-tropic SHIVDH12-CL7 (Sadjadpour 
et al., 2004) and the R5-tropic SHIVAD8EO (Shingai et al., 
2012) during entry to rhesus PBMC in the presence of 
the CXCR4 (AMD3100)- or the CCR5 (AD101)-specific 
inhibitors. Data are representative of two independent 
experiments. (C) Replication kinetics of the X4-tropic 
SHIVDH12-CL7 or the R5-tropic SHIVAD8EO and SHIVDH12-V3AD8 
in rhesus PBMC were determined by measuring the  
32P reverse transcription activity released into the tissue 
culture medium. Data are representative of two inde-
pendent experiments. (D and E) SHIVDH12-V3AD8 repli-
cation in rhesus macaques after inoculation by 
intravenous (n = 5; D) or IR (n = 5; E) routes. Plasma 
viral RNA levels were measured by RT-PCR as previ-
ously described (Endo et al., 2000).
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experiments. As noted earlier, the critical goal of vaccina-
tion, in the case of primate lentiviruses, is sterilizing protec-
tion. Based on the results shown in Fig. 2, five neutralizing 
mAbs were selected for a preexposure passive transfer study: 
VRC01, because it was the first CD4bs NAb of the newly 
isolated broadly acting NAbs to be characterized; the CD4bs 
mAbs 45-46m2 and 3BNC117, both of which exhibited 
strong neutralizing activity against both SHIVAD8EO and 
SHIVDH12-V3AD8; and the gp120 N332 glycan-dependent 
mAbs PGT121 and 10–1074. Comparable but higher IC50 val-
ues for these five mAbs were obtained in a 14-d PBMC-based 
neutralization assay, using replication-competent SHIVAD8EO  
or SHIVDH12-V3AD8 (Table S1).
The protocol used for passive transfer experiments was to 
administer decreasing amounts of neutralizing mAbs intrave-
nously and challenge animals intrarectally 24 h later. Because 
our goal was to block virus acquisition, coupled with the 
knowledge that repeated administrations of human anti-HIV 
mAbs to individual macaques could reduce their potency 
and/or possibly induce anaphylactic responses, we elected to 
use a SHIV challenge dose of sufficient size to establish an 
in vivo infection after a single virus inoculation. In this regard, 
we had previously conducted intrarectal (IR) titrations of 
SHIVAD8 in rhesus monkeys and reported that the inocula-
tion of 103 TCID50, determined by endpoint dilution in rhe-
sus macaque PBMC, was equivalent to administering 3–5 
et al., 2011]) target the gp120 CD4bs and three (10–1074, 
PGT121, and PGT126; Walker et al., 2011a; Mouquet et al., 
2012) are dependent on the presence of the HIV-1 gp120 
N332 glycan, located immediately downstream of the V3 
loop. When tested against SHIVAD8EO, all three glycan- 
dependent mAbs exhibited greater potency than the CD4bs 
mAbs (Fig. 2 A). The IC50 values for the three mAbs target-
ing the gp120 N332 glycan ranged from 0.09 to 0.15 µg/ml 
(Fig. 2 B). The CD4bs mAbs exhibited a much broader range 
(0.14 to 6.36 µg/ml) of IC50 neutralizing activities with 
3BNC117 being the most potent. A similar hierarchy (glycan 
dependent > CD4bs dependent) of neutralizing mAb po-
tency was also observed against SHIVDH12-V3AD8 (Fig. 2 C), 
but the neutralizing activity was distributed across a much 
wider (>800-fold) range compared with the IC50 values ob-
served for SHIVAD8EO (Fig. 2 D). SHIVDH12-V3AD8 was some-
what more sensitive to the glycan-targeting mAbs and more 
resistant to the CD4bs neutralizing mAbs than SHIVAD8EO.
Pre-exposure passive transfer of five mAbs to rhesus 
macaques and challenge with two different R5 SHIVs
Although in vitro neutralization assays can provide impor-
tant information about antibody potency and breadth, and 
guide the development of new mAbs with improved entry 
inhibiting properties, a more relevant test of antiviral efficacy 
is protection against an in vivo challenge in passive transfer 
Table 1. Neutralization phenotypes of primate lentiviruses
Patient serum ID IC50 in TZM-bl cells Tier phenotype
S321 C500 B520 G435 T520b M263 M600c HIVIG
mg/ml
R5 SHIVDH12-V3AD8 321 289 77 172 168 429 134 132 2
R5 SHIVAD8EO 48 36 39 31 41 44 48 1,768 2
X4 SHIVDH12-CL7 110 94 50 65 109 115 65 530 2
HIV-1CAAN5342.A2 84 <20 27 <20 <20 77 185 638 2
HIV-1MN.3 13,944 9,152 822 8,432 3,968 43,722 1,709 1.81 1
IC50 values are the serum dilution at which relative luminescence units (RLUs) were reduced 50% compared with virus control wells (no test sample).
Figure 2. Neutralization of two R5-tropic SHIVs with a 
panel of 11 broadly acting anti–HIV-1 mAbs. (A and C) Neu-
tralization was performed with SHIVAD8EO (A) or SHIVDH12-V3AD8 (C) 
pseudovirions and the indicated mAbs using TZM-bl target cells. 
The titration curves for the glycan-dependent neutralizing mAbs 
are red; for VRC01 in blue; and two potent CD4bs mAbs (45-46m2 
and 3BNC117) in green. (B and D) The calculated IC50 values for 
neutralizing SHIVAD8EO (B) or SHIVDH12-V3AD8 (D) are shown below. 
The individual assays were repeated three times.
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mg/kg) of PGT121 were administered, one of two, two of 
two, and zero of two animals, respectively, were protected 
(Fig. 3 A and Table 2).
The capacity of VRC01 and PGT121 mAbs to block 
SHIVDH12-V3AD8 acquisition was similarly evaluated (Fig. 3 B; 
Table 2). The results obtained with VRC01 were compara-
ble to those observed with the SHIVAD8EO challenge: one of 
two recipients of 30 mg/kg was protected from the estab-
lishment of a SHIVDH12-V3AD8 infection. The PGT121 mAb 
was considerably more potent than VRC01 in preventing 
SHIVDH12-V3AD8 acquisition; pairs of recipients of 20, 1.0, and 
0.2 mg/kg PGT121 resisted infection, but 0.05 mg/kg did 
not. Thus, PGT121 was more effective in preventing 
SHIVDH12-V3AD8 versus SHIVAD8EO in vivo infections (Table 2), 
a result consistent with the 10-fold difference in IC50 values 
for PGT121 for neutralizing the two SHIVs in in vitro assays 
(Fig. 2, B and D).
The results of passively transferring 10–1074, 3BNC117, 
and 45-46m2 neutralizing mAbs to rhesus monkeys, followed 
by a challenge with either SHIVAD8EO or SHIVDH12-V3AD8, are 
summarized in Table 2. We had previously reported that the 
10–1074 and 3BNC117 mAbs prevented the acquisition of 
SHIVAD8EO infection when administered at a dose of 5 mg/kg, 
but not at 1 mg/kg (Shingai et al., 2013). In the case of 
SHIVDH12-V3AD8 challenges, the N332-dependent 10–1074 mAb 
potently blocked infection at 5 mg/kg and protected one of 
two monkeys at a dose of 1 mg/kg. 3BNC117 successfully 
prevented the acquisition of a SHIVDH12-V3AD8 infection in one 
of two monkeys at doses of 5 mg/kg and 1 mg/kg (Table 2). 
Surprisingly, despite exhibiting potent neutralizing activities 
against both viruses in vitro (Fig. 2), the 45-46m2 CD4bs 
mAb failed to block the acquisition of either SHIV at any 
dose administered (Table 2).
animal infectious doses50 (AID50; Gautam et al., 2012). In 
fact, single IR inoculations of 3 to 5 AID50 have resulted in 
the successful establishment of infection in 20 of 20 rhesus 
macaques with SHIVAD8EO or SHIVDH12-V3AD8. Pathogenic 
molecularly cloned viruses rather than uncloned SHIV stocks 
were used as inocula to facilitate the identification of neutral-
ization resistant viral variants emerging after challenge.
As a control for the first passive transfer experiment, an 
anti–dengue virus NS1 IgG1 mAb was administered intrave-
nously to two animals, which were challenged by the IR 
route with SHIVAD8EO 24 h later. Both monkeys (ML1 and 
MAA) rapidly became infected, generating peak levels of 
plasma viremia 14 to 17 d PI (Fig. 3 A). VRC01 was the first 
anti–HIV-1 neutralizing mAb tested for protection against 
SHIVAD8EO acquisition and was administered to two macaques 
at a dose of 50 mg/kg. One (DEGF) of the two inoculated ma-
caques was completely protected from the SHIVAD8EO chal-
lenge, with no evidence of plasma viremia or cell-associated 
viral DNA over a 45-wk observation period. The other re-
cipient of 50 mg/kg VRC01 (DEH3) became infected, but 
peak plasma viremia was delayed until week 5 PI. Two addi-
tional macaques administered lower amounts (20 mg/kg) of 
VRC01 were not protected from the SHIVAD8EO challenge 
(Fig. 3 A). These results are summarized in Table 2.
We next examined the protective properties of PGT121 
against a SHIVAD8EO challenge. PGT121 was one of the most 
potent glycan-targeting neutralizing mAbs measured in the 
TZM-bl assay (Fig. 2). Based on the results obtained with 
VRC01 and the fact that PGT 121 was more potent in the 
in vitro assay, we began the in vivo PGT121 mAb titration at 
20 mg/kg. As shown in Fig. 3 A, both monkeys (KNX and 
MK4) receiving 20 mg/kg PGT121 resisted the SHIVAD8EO 
challenge. When lower amounts (5 mg/kg, 1 mg/kg, or 0.2 
Figure 3. Passive transfer of VRC01 or PGT121 
mAbs and subsequent challenge with two differ-
ent R5-tropic SHIVs. (A and B) Plasma viral loads in 
rhesus monkeys, administered VRC01 or PGT121 and 
challenged by the IR route 24 h later with SHIVAD8EO 
(n = 14; A) or SHIVDH12-V3AD8 (n = 14; B), were deter-
mined by RT-PCR. The amounts of mAb injected in-
travenously (mg/kg) are indicated in parentheses  
for each animal. Macaques ML1 and MAA received  
20 mg/kg of control anti–dengue virus NS1 IgG1 
mAb. Human IgG from uninfected individuals was 
also transferred to macaques JII and JKI as a  
negative control.
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Table 2. Plasma neutralizing antibody concentrations and titers at the time of virus challenge
Animal ID Abs Dosage PROTECTED Ab concentration at day 0 Titer (TZM-bl) at day 0
mg/kg µg/ml
SHIVAD8EO Challenged Animals
DEGF VRC01 50 Yes 586.9 1:162
DEH3 No 711.0 1:176
DE1L 20 No 206.5 1:65
JBN No 188.1 1:80
KNX PGT121 20 Yes 267.9 1:2,495
MK4 Yes 253.6 1:2,773
DE9J 5 Yes 55.7 1:563
PNR No 47.2 1:618
DCGI 1 Yes 24.0 1:116
KNE Yes 19.7 1:55
K44 0.2 No 1.8 <1:20
K49 No 1.8 1:17
DEEM 10-1074 20 Yes 289.8 1:2,004
KIL Yes 257.7 1:2,075
ME1 5 Yes 112.9 1:633
PNV Yes 117.5 1:384
PID 1 No 19.9 1:56
DCHX No 24.8 1:53
PZE 3BNC117 5 Yes 105.4 1:272
PM5 Yes 76.1 1:372
KMH 1 No 39.6 1:55
MJ5 No 15.1 1:75
PLD 45-46m2 20 No 15.0 1:27
MA9 No 17.6 <1:20
MC6 5 No 2.3 <1:20
DE0CA No 2.2 <1:20
ML1 DEN3 20 No ND <1:20
MAA No ND <1:20
SHIVDH12-V3AD8 Challenged Animals
DEJ3 VRC01 30 Yes 395.8 1:52
KZ1 No 306.0 1:70
KZA PGT121 20 Yes 215.1 1: 13,120
DECT Yes 200.7 1: 13,805
KTL Yes 282.7 1: 12,669
PZ9 Yes 133.1 1: 12,055
K2Z 1 Yes 15.1 1:422
MT8 No 29.3 1:539
DEEB 0.2 Yes 3.1 1:159
DEP2 Yes 1.6 1:101
MFD 0.05 No 1.0 <1:20
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This time point was chosen because it corresponds to the time 
of SHIV challenge in the preexposure passive transfer experi-
ments. Replicate samples were obtained from 11 different tis-
sues of each animal at the time of necropsy. Triplicate T-PER 
cell lysates or PBS cell suspensions were independently pre-
pared and analyzed for the presence of gp120-bound 3BNC117 
by ELISA, using a specific anti–human IgG antibody. As 
shown in Table 3, 3BNC117 was not only measurable in 
plasma but was readily detectable at concentrations ranging 
from 10 to 75× lower than in plasma in replicate cell suspen-
sions and lysates from multiple lymphoid tissues, GI tract 
mucosal preparations, vaginal specimens, and liver from both 
animals 24 h after administration. Although significantly lower 
than plasma levels, the levels in tissues are higher than the lev-
els required for neutralization in vitro. Comparable levels of 
mAb were also detected in the same replicate tissue suspen-
sions and lysates from monkey A11E039 when an anti-idiotype, 
specific for the 3BNC117, was used in ELISA (unpublished 
data). No anti-HIV antibody was detectable in tissue suspen-
sions or lysates prepared from a control animal (ELB) which 
did not receive 3BNC117.
We also attempted to measure anti-HIV antibody on the 
moist surfaces of nonlymphoid tissues immediately after their 
removal at necropsy. Cellulose wicks were applied in tripli-
cate to these specimens for 5 min to absorb surface secretions, 
Plasma concentrations at the time of challenge  
and pharmacokinetics of mAbs after passive transfer
The amount of mAb administered to this cohort of macaques 
was selected based primarily on the results of the in vitro neu-
tralization assays shown in Fig. 2. One of our goals was 
to identify a plasma mAb concentration conferring steriliz-
ing protection. With the exception of the 45-46m2 mAb, the 
plasma concentrations for a given dose (e.g., 20 mg/kg) of 
each of the anti-HIV mAbs at the time of challenge (24 h after 
antibody administration) were similar in all animals (Table 2). 
However, the plasma concentrations of different mAbs needed 
to prevent SHIVAD8EO or SHIVDH12-V3AD8 acquisition varied 
greatly. PGT121 was clearly the most effective against both 
viruses, with SHIVDH12-V3AD8 exhibiting somewhat greater 
sensitivity to this mAb (two of two monkeys protected at 
a plasma concentration of 0.2 µg/ml). In contrast, a plasma 
concentration of nearly 400 µg/ml of VRC01 was required 
to protect one of two animals against the same SHIVDH12-
V3AD8 challenge virus (Table 2). The most potent CD4bs 
mAb administered to macaques in this study, 3BNC117, was 
6–10-fold more effective than VRC01 in preventing the 
acquisition of either SHIV.
Neutralizing mAb levels were also measured in several tis-
sues from two rhesus macaques (A11E039 and MIB), sacri-
ficed 24 h after the administration of 20 mg/kg of 3BNC117. 
Animal ID Abs Dosage PROTECTED Ab concentration at day 0 Titer (TZM-bl) at day 0
KIA No 1.3 <1:20
KIM 10-1074 20 Yes 290.3 1:1,972
KWM Yes 173.3 1:2,282
MJW 5 Yes 96.6 1:420
MJT Yes 95.3 1:376
DENI 1 Yes 28.4 1:106
JHZ No 18.6 1:136
HE8 0.2 No 19.4 1:39
KCZ No 19.7 1:35
MFBA 3BNC117 20 Yes 294.9 1:143
MER Yes 272.7 1:142
KIV 5 Yes 114.6 1:80
KPI No 133.1 1:90
DE9D 1 No 23.3 1:20
DEW7 Yes 29.6 1:18
MEV 0.2 No 3.9 <1:20
MF9 No 5.7 <1:20
KZMA 45-46m2 5 No 2.1 ND
KNP No 4.0 ND
JII hu-IgG 100 No ND ND
JK1 No ND ND
ND, not done.
Table 2. Plasma neutralizing antibody concentrations and titers at the time of virus challenge (Continued)
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Table 3. NAb concentrations in tissues 24 h after passive transfer
Tissue A11E039 (20 mg/kg 3BNC117) MIB (20 mg/kg 3BNC117) ELB (control)
Plasma Plasma CSF Plasma Plasma CSF Plasma CSF
T = 0 T = 24 h T = 24 h T = 0 T = 24 h T = 24 h
1.29  
µg/ml
137.22 
µg/ml
<1 µg/ml <0.5 µg/ml 158.53 
µg/ml
<0.5  
µg/ml
1.28 µg/ml <0.5 µg/ml
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3
µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g µg/g
Cell Lysates
Axillary LN 9.26 8.46 7.53 5.04 5.27 5.09 <0.5 <0.5 <0.5
Inguinal LN 5.91 13.07 7.19 6.30 6.35 5.89 <0.5 <0.5 <0.5
Mesenteric 
LN
12.03 11.65 13.01 9.05 10.94 10.57 <0.5 <0.5 <0.5
Colonic LN 8.92 10.01 7.11 6.34 7.03 6.86 <0.5 <0.5 <0.5
Spleen 7.04 6.34 6.20 4.74 5.87 10.45 <0.5 <0.5 <0.5
Liver 8.50 7.74 13.01 6.74 7.36 4.97 <0.5 <0.5 <0.5
Jejunum 5.20 9.06 7.26 0.60 <0.5 <0.5 <0.5 <0.5 <0.5
Colon 5.22 5.54 4.97 1.40 1.30 1.42 <0.5 <0.5 <0.5
Rectum 7.39 4.93 5.42 1.95 2.39 2.59 <0.5 <0.5 <0.5
Ileum 4.26 5.11 4.58 0.69 0.72 0.66 <0.5 <0.5 <0.5
Vagina 1.34 3.67 2.20 3.29 4.01 7.40 <0.5 <0.5 <0.5
Cell 
Suspensions
Axillary LN 12.07 17.60 13.23 6.00 5.77 4.24 <0.5 <0.5 <0.5
Inguinal LN 13.16 11.62 6.38 3.89 4.06 4.48 <0.5 <0.5 <0.5
Mesenteric 
LN
12.42 13.45 12.14 8.06 8.27 9.14 <0.5 <0.5 <0.5
Colonic LN 10.31 8.37 5.66 6.70 4.55 5.61 <0.5 <0.5 <0.5
Spleen 6.39 6.42 4.65 4.69 5.18 4.76 <0.5 <0.5 <0.5
Liver 10.44 10.69 13.56 4.84 4.80 5.39 <0.5 <0.5 <0.5
Jejunum 6.17 3.34 3.86 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5
Colon 8.81 9.12 10.50 2.08 1.53 1.32 <0.5 <0.5 <0.5
Rectum 3.57 5.52 3.44 2.45 2.53 4.10 <0.5 <0.5 <0.5
Ileum 2.37 <1 1.33 0.75 0.93 0.59 <0.5 <0.5 <0.5
Vagina 2.76 4.19 3.39 6.78 3.14 3.37 <0.5 <0.5 <0.5
Wick Filtrates
Spleen 14.65 11.40 ND <0.75 <0.75 <0.75 <0.75 <0.75 <0.75
Liver 57.83 50.04 57.71 57.47 38.60 36.35 1.33 1.20 0.80
Jejunum <1.5 <1.5 <1.5 <0.75 <0.75 <0.75 <0.75 <0.75 <0.75
Colon <1.5 <1.5 ND <0.75 <0.75 <0.75 <0.75 <0.75 <0.75
Rectum 1.55 <1.5 <1.5 1.27 <0.75 2.73 <0.75 <0.75 <0.75
Ileum <1.5 <1.5 <1.5 <0.75 <0.75 <0.75 <0.75 <0.75 <0.75
Vagina 4.51 3.52 5.53 4.61 1.61 <0.75 <0.75 <0.75 <0.75
ND, not done. T, sample collection time after NAb administration
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was not directly determinable. Based on the plasma mAb 
concentrations in several macaques 24 h after the adminis-
tration of 20 mg/kg of the VRC101, PGT121, 10–1074, 
and 3BNC117 neutralizing mAbs (250 µg/ml; Table 2), 
the two monkeys receiving 20 mg/kg 45-46m2 had plasma 
mAb concentrations of only 15.0 and 17.6 µg/ml, represent-
ing a decay of >95% relative to other neutralizing mAbs 
within 24 h of administration (Fig. 4). Thus, despite its high 
potency as measured in vitro (Fig. 2), 45-46m2 was ineffec-
tive in macaques.
Neutralizing titers are predictive of protection
The plasma antibody concentrations for each of the five anti-
HIV monoclonal NAbs conferring sterilizing protection 
against SHIVAD8EO or SHIVDH12-V3AD8 are shown in Fig. 5 A. 
These protective concentrations ranged from 587 to 1.6 µg/ml 
(Table 2). The titers of neutralizing activity in the plasma of 
monkeys at the time of SHIV challenge are a more informative 
weighed, centrifuged in cellulose acetate filter columns, and as-
sayed for HIV antibody in the filtrate by ELISA. As indicated 
in Table 3, 3BNC117 was found on the surface of vaginal mu-
cosa samples from both monkeys but was below detectable lev-
els in assays of GI tract specimens. The high levels of HIV 
antibody detected in liver samples with the wick system very 
likely reflect 3BNC117 in blood on the cut surfaces of this 
organ. Collectively, the results presented in Table 3 demonstrate 
that the intravenous administration of anti-HIV neutralizing 
mAb is rapidly and systemically disseminated to tissues, and 
present at levels capable of blocking the establishment of a 
SHIV infection at the site of virus inoculation.
The ineffectiveness and unexpectedly low plasma levels 
of the 45-46m2 mAb (Table 2) led us to determine the decay 
rates of all five neutralizing mAbs administered to macaques 
(Fig. 4). The calculated half-lives of PGT121, 10–1074, 
3BNC117, and VRC01 mAbs were quite similar: 3.5, 3.5, 3.3, 
and 3.1 d, respectively. In contrast, the half-life of 45-46m2 
Figure 5. Levels of neutralizing mAbs in the plasma of passively transferred macaques at the time of challenge. (A) The concentrations (µg/ml) 
of the indicated mAbs in plasma 24 h after passive transfer of mAbs were determined by ELISA using recombinant HIV-1 gp120. (B) The plasma IC50 titers 
of the indicated mAbs 24 h after passive transfer of mAbs were determined using the TZM-bl cell assay. Red circles indicate protected (no acquisition) 
monkeys; black circles denote infected animals. Plasma antibody levels and NAb titers were measured in the 60 animals described in Table 2.
Figure 4. Levels of neutralizing mAbs in 
the plasma of passively transferred ma-
caques. The concentrations of the indicated 
mAbs in plasma at various times after admin-
istration were determined by ELISA using 
recombinant HIV-1 gp120. Plasma antibody 
levels were measured in the animals described 
in Table 2. Means and SDs are shown.
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mAbs to 60 animals, challenged by identical routes and inoc-
ulum size but with two SHIVs bearing genetically distinct 
envelope glycoproteins, the neutralization data from all of the 
monkeys were combined and subjected to probit regression 
to determine the relationship between plasma neutralization 
titers and in vivo protection (Finley, 2007). As a further check, 
when a term for the SHIV virus was included in the probit 
regression model on all 60 macaques, there was no evidence 
of a difference between the two SHIV viruses (P = 0.16). 
When applied to the entire group of 60 macaques, probit re-
gression estimated that a plasma neutralization titer of 1:104.5 
would prevent virus acquisition in 50% of animals (Fig. 6). 
The inset at the bottom of Fig. 6 predicts the neutralization 
titers, determined by TZM-bl assay and calculated by probit 
regression, needed to protect different proportions of a SHIV-
exposed monkey population. For example, a neutralization 
titer of 1:328.7 would be required for protection of 80% of 
challenged animals, with the caveat that the 90% confidence 
interval of titers to achieve this outcome is quite large (1:152 
to 1:632).
DISCUSSION
This study has broader implications beyond simply being an-
other preexposure passive transfer experiment using recently 
developed broad and potent anti-HIV neutralizing mAbs. 
It reaches the optimistic conclusion that if an immunogen 
can be identified/designed to elicit the breadth of anti-HIV 
neutralizing activity possessed by some of the new genera-
tion of mAbs, a vaccine containing such an immunogen may 
only have to generate modest protective titers to prevent the 
and functional metric of circulating anti–HIV-1 NAbs than 
their IgG concentrations. Presentation of data in this format 
would clearly be relevant for vaccine development where titers 
of circulating antivirus neutralizing activity, not plasma antibody 
concentrations, could be correlated with in vivo protection. 
Neutralization titers were therefore measured on plasma sam-
ples collected 24 h after mAb administration when the ma-
caques were challenged with SHIVAD8EO or SHIVDH12-V3AD8 
(Table 2). When this is done, a relatively weak mAb such as 
VRC01, when administered at a dose of 30 or 50 mg/kg, 
generates protective plasma neutralization titers in the 1:100 
range, whereas the more potent PGT121 mAb can achieve 
this same level of activity after the administration of only 
0.2 mg/kg. The neutralization titers in the entire cohort of 
macaques at the time of virus challenge as well as in those 
protected from infection are shown graphically in Fig. 5 B. 
This presentation of plasma neutralizing activity suggests that 
a neutralization titer of 1:100 may be a possible threshold re-
quired to prevent virus acquisition.
The method described by Reed and Muench (1938) was 
next used to calculate the neutralization titers, measured in 
plasma, needed to prevent virus acquisition in 50% of chal-
lenged monkeys. These protective titers for the 28 monkeys, 
challenged with SHIVAD8EO, or the 32 monkeys, challenged 
with SHIVDH12-V3AD8, were separately deduced (Tables S2 
and S3). The plasma neutralization titers required for protect-
ing 50% of the SHIVAD8EO or SHIVDH12-V3AD8 challenged 
animals were calculated to be 1:115 and 1:96, respectively. 
Because these two titers were quite similar and were obtained 
after the administration of the same ensemble of neutralizing 
Figure 6. Probit regression analysis relating NAb titers at 
the time of virus challenge and probability of protection. 
The black circles denote SHIVAD8EO challenged monkeys; the red 
circles denote SHIVDH12-V3AD8 challenged monkeys. Horizontal 
lines indicate 90% confidence intervals of plasma neutralization 
titers for 33, 50, 80, 90, and 95% probability of protection. The 
estimated neutralization titers in plasma conferring different 
levels of protection and their corresponding 90% confidence 
intervals are shown at the bottom of the figure.
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Hessell et al., 2010). For example, it was recently reported that 
plasma neutralizing titers ranging from 1:200 to 1:495, achieved 
after the administration of a single potent anti-HIV mAb 
(PGT121), protected 3 of 5 macaques from a vaginal chal-
lenge with the R5-tropic SHIVSF162P3 (Moldt et al., 2012). 
The 1:100 protective neutralization titer reported in our 
study was calculated for a cohort of 60 macaque recipients of 
5 different potent anti-HIV mAbs and challenged with either 
of two R5-tropic SHIVs by the IR route. It is also worth not-
ing that neutralizing titers in the 1:100 range are attainable by 
the human immune system, based on a recent study showing 
that 34% of 463 sera from chronically HIV-infected individu-
als had neutralizing titers >1:100 when tested against viral 
strains from 4 or more HIV-1 clades (Simek et al., 2009). 
Given the caveats regarding the 3–5 AID50 inoculum size used 
in this study, the reported 1:100 value should not be regarded 
as a rigid and fixed number, as indicated by the titers mea-
sured in some of the unprotected macaques. It was calculated 
from the results obtained from a large number of animals and 
should be considered to be a minimal number to be achieved 
by a new generation of immunogens.
With respect to generating the modest protective neutral-
izing titers preventing virus acquisition, it is now appreciated 
that the very large number of genetic changes (40–100 nucle-
otides) attending the maturation of B cells, capable of pro-
ducing potent and broadly acting anti-HIV NAbs, poses a 
major impediment for developing an effective viral vaccine 
(Scheid et al., 2009; Walker et al., 2009, 2011a; Xiao et al., 
2009; Wu et al., 2010; Scheid et al., 2011; Mouquet et al., 
2012; Klein et al., 2013a). This number far exceeds the nu-
cleotide changes required to produce protective antibodies 
against most other viral pathogens and makes the design of an 
efficacious immunogen a most difficult challenge. Several 
possible solutions have been proposed to address this issue. 
One, suggested from natural HIV infections of humans and 
SHIV infections of macaques, involves the identification and 
use of unique HIV-1 envelope glycoproteins, able to guide 
the development of potent neutralizing activity after the ini-
tial encounter with the immune system (Walker et al., 2011b; 
Shingai et al., 2012; Klein et al., 2013b; Doria-Rose et al., 
2014). Another utilizes epitope-focused and scaffold-based 
immunogens, similar to those recently reported for an anti-
respiratory syncytial virus vaccine (Correia et al., 2014), that 
specifically target structurally defined epitopes for known 
protective NAbs, and which are also able to interact with 
germline IgG ( Jardine et al., 2013; Klein et al., 2013b).
Two interesting findings relevant to the selection and 
clinical use of antiviral neutralizing mAbs emerged from this 
study. First, the intravenous administration of such antibodies 
resulted in their rapid dissemination systemically. They be-
came detectable in several lymphoid and mucosal tissues 
within 24 h, reaching levels of activity sufficient to block 
virus acquisition even when administered at a dosage as low 
as 0.2 mg/kg. Second, virus neutralization measured in vitro 
is not absolutely predictive of neutralizing activity achieved 
in vivo. Although the results obtained using the TZM-bl cell 
establishment of infection. It should be noted that the chal-
lenge virus inoculum size (3–5 AID50) used in this study was 
selected to ensure that all of the monkeys would be infected 
after a single IR inoculation. This challenge dose is orders of 
magnitude higher than that estimated to establish an HIV-1 
infection after vaginal exposure in humans (4–8 per 10,000 
exposures; Patel et al., 2014). If, in fact, the calculated 50% 
protective titer of 1:100 against a virus challenge of 3–5 
AID represents a gross overestimate, then the true protective 
titer might be tempered by recent studies reporting that 
10–20-fold higher levels of neutralizing activity are required 
to block spread by cell-associated virus in tissue culture sys-
tems (Abela et al., 2012; Malbec et al., 2013).
The identification and development of immunogens ca-
pable of inducing neutralizing activities possessing the breadth 
of the newest generation of antiviral mAbs and generating 
plasma titers in the 1:100 range is a major challenge facing the 
HIV vaccine field. Several vaccine studies have immunized 
macaques with the SHIVSF162P4 envelope glycoprotein or its 
gp120V2del derivative (Barnett et al., 2008, 2010; Bogers et al., 
2008; Page et al., 2012). Others have used HIV-1YU-2 gp120 
trimers (Sundling et al., 2010a,b) or trimerized consensus 
HIV-1 gp140 proteins (Eugene et al., 2013). Protective effi-
cacy was evaluated using easy-to-neutralize challenge viruses 
such as the closely related SHIVSF162P4 or SHIV89.6P, and 
SHIVsbg. In some instances, modest levels of antivirus neu-
tralizing activity against some Tier 1 HIV-1 isolates were in-
duced before virus challenge and, in a few cases, homologous 
virus acquisition appeared to be blocked (Bogers et al., 2008; 
Barnett et al., 2010). However, the levels of NAbs conferring 
sterilizing protection could not be readily determined from 
these studies. For example, in one study using a homologous 
challenge, virus was undetectable in five of eight vaccinated 
monkeys with preexposure anti-SHIVSF162P4 NAb titers rang-
ing from 1:80 to 1:700 (Bogers et al., 2008). In another study, 
heterologous SHIVSF162P4 acquisition was blocked in 2 of 4 
animals vaccinated with HIV-1 gp120 consensus envelope 
trimers, which had induced anti–HIV-1SF162 neutralizing ti-
ters of 1:40 and 1:320 (Eugene et al., 2013). However, one 
of the two protected macaques carried the Mamu B*08 
MHC allele and the other animal released virus after the ad-
ministration of the depleting anti-CD8 mAb, M-T807R1, 
indicating that SHIV acquisition had not been blocked. 
A recent study using adenovirus and poxvirus vector-based 
vaccines, which expressed mosaic HIV-1 Env/Gag/Pol im-
munogens, induced NAb titers in the 1:69 to 1:153 range 
against Tier 1 viral strains in rhesus macaques (Barouch 
et al., 2013a). This latter vaccine regimen, followed by re-
peated low-dose challenges with the difficult-to-neutralize 
SHIVSF162P3, reduced the per-exposure virus acquisition risk 
by 90%.
Earlier passive transfer studies have estimated protective 
plasma neutralizing concentrations and/or neutralization titers 
using a variety of less potent and more narrowly focused mAbs, 
X4- or R5-tropic SHIVs, and different routes of inoculation 
(Mascola et al., 1999; Shibata et al., 1999; Parren et al., 2001; 
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Lipofectamine 2000 (Invitrogen). Culture supernatants were collected 48 h 
later and aliquots stored at 80°C until use. Concanavalin A–stimulated 
rhesus PBMCs (2 × 106 cells in 500 µl) were infected with transfected cell 
supernatants by spinoculation (O’Doherty et al., 2000) for 1 h, mixed with 
the same number/volume of activated PBMC, and cultures were maintained 
for at least 12 d with daily replacement of culture medium. Samples of super-
natant medium were pooled around the times of peak reverse transcriptase 
production to prepare individual virus stocks.
Antibodies. 11 mAbs (VRC01, NIH45-46, 45-46G54W, 45-46m2, 
3BNC117, 12A12, 1NC9, and 8ANC195, 10–1074, PGT121, and PGT126) 
were isolated and produced as previously described (Zhou et al., 2010; Diskin 
et al., 2011, 2013; Scheid et al., 2011; Walker et al., 2011a; Mouquet et al., 2012). 
The 45-46G54W and 45-46m2 mAbs were provided by P. Marcovecchio and 
H. Gao (California Institute of Technology, Pasadena, CA). DEN3, a dengue 
virus NS1-specific human IgG1 mAb (Moldt et al., 2012) or control human 
IgG (NIH Nonhuman Primate Reagent Resource) were used as the negative 
control antibodies in this study. The mAbs selected for preexposure passive 
transfer were administered intravenously 24 h before virus challenge.
Quantitation of plasma viral RNA levels. Viral RNA levels in plasma 
were determined by real-time reverse transcription PCR (Prism 7900HT se-
quence detection system; Applied Biosystems) as previously reported (Endo 
et al., 2000).
Antibody concentrations in plasma. The concentrations of administered 
mAbs in monkey plasma were determined by ELISA, using recombinant 
HIV-1JRFL gp120 (Progenics Pharmaceuticals) or HIVIIIB (Advanced Bio-
technology Inc.) as previously described (Parren et al., 2001). In brief, mi-
crotiter plates were coated with 2 µg/ml HIV-1 gp120 and incubated 
overnight at 4°C. The plates were washed with PBS/0.05% Tween-20 and 
blocked with 1% (vol/vol) BSA. After blocking, serial dilution of antibodies 
or plasma samples were added to the plate and incubated for 1 h at room 
temperature. Binding was detected with a goat anti–human IgG F(ab)2 frag-
ments coupled to alkaline phosphatase (Thermo Fisher Scientific) and visualized 
with SIGMAFAST OPD (Sigma-Aldrich). The decay half-lives of neutral-
izing mAbs were calculated by a single-exponential decay formula based on 
the plasma concentrations beginning on day 5 or day 7 after antibody admin-
istration (Hessell et al., 2010).
Antibody concentrations in tissue. The following tissues were collected 
from two rhesus monkeys sacrificed 24 h after the administration of 20 mg/kg 
of the 3BNC117 mAb or from a single control animal receiving no anti-
body: axillary, inguinal, mesenteric, and colonic lymph nodes; or spleen, 
liver, jejunum, colon, ileum, rectum, and vagina. Several independent sam-
ples were collected from each tissue specimen and weighed (40–300 mg). To 
generate cell suspensions, three samples from each tissue were immediately 
homogenized in 4× volume (wt/vol) of PBS using disposable pestles (Axy-
gen, Inc.) and centrifuged at 12,000 rpm for 10 min at 4°C. The collected 
supernatants were filtered through 0.45-µm–pore size Spin-X (Corning). 
Cell lysates were prepared from three other samples from the same tissue, 
suspended in 4× volume (wt/vol) of T-PER (Thermo Fisher Scientific), and 
homogenized using disposable pestles. The protein extracts obtained were 
centrifuged at 12,000 rpm for 10 min at 4°C and the middle protein layer 
was collected and recentrifuged under the same conditions. The recovered 
cell lysate was filtered through a 0.45-µm–pore size Spin-X column, and 
frozen until assay by ELISA.
Antibody on the surfaces of vaginal, intestinal, splenic, and hepatic tis-
sues collected at necropsy was absorbed to individual cellulose wicks 
(WECK-CEL Cellulose; Beaver-Visitec International, Inc.) for 5 min and 
measured as previously described (Kozlowski et al., 2000; Moldt et al., 
2012). Wicks were weighed before and after their application to individual 
tissue specimens and then placed in a 0.45-µm–pore size Spin-X column. 
After a 15-min incubation in 9× (wt/vol) of PBS at 4°C, filtrates were col-
lected by centrifugation and frozen until assay by ELISA.
assay correlated well with the in vivo protective effects for 
four (PGT121, 10–1074, 3BNC117, and VRC01) of the 
anti-HIV mAbs (Fig. 2 and Table 2), the in vitro engineered 
45-46m2 CD4bs mAb, which exhibited very high potency 
in vitro, was a complete failure in vivo. It exhibited an ex-
tremely short half-life in plasma, with only 5% activity re-
maining in the circulation by 24 h after administration.
The in vivo decay of the broadly acting anti-HIV mAbs 
used in this study was relatively short (half-life = 3.5 d), most 
likely reflecting their human rather than macaque origin, 
which very likely contributed to this rapid decline. Nonethe-
less, the administration of high-dose combination neutraliz-
ing mAb treatment, including three of the antibodies assessed 
here (3BNC117, 10–1074, and PGT121), has recently been 
reported to suppress plasma viremia to the limits of detection 
in chronically SHIVAD8- or SHIVSF162-infected macaques 
(Barouch et al., 2013b; Shingai et al., 2013). In this regard, 
before the development of an effective vaccine, preexposure 
immunoprophylaxis against hepatitis A virus infection by ad-
ministering 0.06 ml/kg of immune globulin intramuscularly 
was common practice, and conferred protection for 3–5 mo 
(Advisory Committee on Immunization Practices et al., 2006). 
It is therefore not unreasonable to envisage the future devel-
opment and use of reengineered derivatives of anti-HIV mAbs 
with greatly extended half-lives. Genetic modification of the 
existing anti-HIV mAbs could prolong their neutralizing ac-
tivities in vivo for long periods of time, allowing semiannual 
or annual immunizations as an alternative to vaccination.
MATERIALS AND METHODS
Animal experiments. All animals were housed and cared for in accordance 
with the American Association for Accreditation of Laboratory Animal Care 
standards in American Association for Accreditation of Laboratory Animal 
Care–accredited facilities, and all animal procedures and experiments were 
performed according to protocols approved by the Institutional Animal Care 
and Use Committee of the National Institute of Allergy and Infectious Dis-
eases (NIAID), National Institutes of Health (NIH). 60 male and female 
rhesus macaques (Macaca mulatta) of Indian genetic origin ranging from 2 to 
10 yr of age were maintained in accordance with NIH guidelines (Committee, 
1985) and were housed in a biosafety level 2 NIAID facility. Phlebotomies, 
euthanasia, and sample collection were performed as previously described 
(Endo et al., 2000). The macaques used in this study were negative for the 
MHC class I Mamu-A*01 allele. For SHIV inoculations, a pediatric specu-
lum was used to gently open the rectum and a 1 ml suspension of virus in a 
tuberculin syringe was slowly infused into the rectal cavity.
Construction of the R5-tropic SHIVDH12-V3AD8. PCR mutagenesis, 
with primers corresponding to the 5 and 3 halves of the SHIVAD8EO 
(Shingai et al., 2012) gp120 V3 coding region (forward primer: 5-AGAG-
CATTTTATACAACAGGAGACATAATAGGAGATATAAGACAAGCA-
CATTGCAACATTAGTAAAGTAAAATGGC-3; and reverse primer: 
5-TCCTGGTCCTATATGTATACTTTTCCTTGTATTGTTGTTGGG-
TCTTGTACAATTAATTTCTACAGTTTCATTC-3), was used to intro-
duce these V3 sequences into the genetic background of the pSHIVDH12-CL7 
molecular clone (Sadjadpour et al., 2004) using Platinum PFX DNA poly-
merase (Invitrogen). After gel purification, the PCR product was treated 
with T4 polynucleotide kinase (Gibco) and blunt-end ligated to create 
pSHIVDH12-V3AD8, which was used to transform competent cells.
Viruses. Virus stocks were prepared by first transfecting 293T cells with the 
SHIVAD8EO (Shingai et al., 2012) or SHIVDH12-V3AD8 molecular clones using 
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